The European Medicines Agency is busy analyzing the applications it has received from people interested in attending its first ever public hearing on the safety of marketed medicines that is scheduled to take place on Sept. 26, and which will focus on valproate-containing medicines.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?